Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 296

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 296
---
 |     |        |   1,191 |   |     |        |  - |   |     |            |    633,345 |   |     |              | -          |   |     |             | -           |   |     |       |     633,345 |   |
| Opening                                                                 
 Equity at February 14, 2024 (Successor)                                 |     |                 | 10,039 |     | $      | 8,937,852 |     |        | 145,318 |   |     | $      | 15 |   |     | $          | 53,899,871 |   |     | $            | (2,000,000 | ) |     | $           | (63,185,641 | ) |     | $     |  (2,347,903 | ) |

F-9 Going concern– The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its research and development (“R&D”) activities and meet its obligations on a timely basis. As of September 30, 2024, the Company reported $ 3.4million of cash, restricted cash and cash equivalents, with an accumulated deficit of $ 71.6million. Additional funds are necessary to maintain current operations and to continue R&D activities. The Company expects to seek additional funding in the form of equity financings or debt, however, there can be no assurance that sufficient funding will be available to allow the Company to successfully continue its R&D activities and planned regulatory filings with the FDA. If the Company is unable to obtain necessary funds, significant reductions in spending and the delay or cancellation of planned activities may be necessary. These actions would have a material adverse effect on the Company’s business, results of operations, and prospects. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these financial statements are issued. The accompanying unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Risks and uncertainties– The Company is subject to all of the risks inherent in an early-stage biotechnology company.